tldrdailynews.com logo

Eli Lilly Acquires Sigilon Therapeutics, Expanding Diabetes Treatments

1 min read
Source: Reuters
Eli Lilly Acquires Sigilon Therapeutics, Expanding Diabetes Treatments
Photo: Reuters
TL;DR

Pharmaceutical company Eli Lilly has announced its plans to acquire the remaining shares of Sigilon Therapeutics, a company specializing in experimental cell therapies for diabetes patients. The deal, valued at $34.6 million in upfront cash, will provide Lilly with access to Sigilon's proprietary cell therapy candidate for treating type 1 diabetes. The acquisition is expected to close in the third quarter of 2023.

Topics:businesshealthcare#acquisition#cell-therapies#diabetes-treatments#eli-lilly#healthcare#sigilon-therapeutics
Share this article
  1. Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments  Reuters
  2. Lilly to Acquire Sigilon Therapeutics | Eli Lilly and Company  Investors | Eli Lilly and Company
  3. Biotech Stock Sigilon Scores Eli Lilly Buyout And Catapults By Triple Digits | Investor's Business Daily  Investor's Business Daily
  4. Lilly buys diabetes cell therapy partner Sigilon for $35M  FierceBiotech
  5. Sigilon Therapeutics Shares Are Shooting Higher Today - What's Going On  Yahoo Finance

Want the full story? Read the original reporting

Read on Reuters